Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics. The company operates through two primary business segments: therapeutics and vaccines, leveraging proprietary platform technologies to advance its pipeline of… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arcturus Therapeutics Holdings Inc. does
In the company’s own words
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics. The company operates through two primary business segments: therapeutics and vaccines, leveraging proprietary platform technologies to advance its pipeline of mRNA-based treatments.
The company's core therapeutic programs target rare genetic disorders with significant unmet medical needs. ARCT-032 is in Phase 2 clinical development for cystic fibrosis, utilizing the company's LUNAR lipid-mediated delivery system to deliver codon-optimized CFTR mRNA to airway epithelial cells. ARCT-810 is in Phase 2 development for ornithine transcarbamylase deficiency, a rare metabolic disorder affecting the urea cycle. Both candidates have received orphan drug designations from the FDA and EMA.
Arcturus' vaccine program centers on KOSTAIVE, the world's first approved self-amplifying mRNA vaccine. Developed using the company's proprietary STARR self-amplifying mRNA technology platform combined with LUNAR delivery technology, KOSTAIVE has achieved regulatory approval in Japan, the European Union, and the United Kingdom for COVID-19 prevention. Commercial sales commenced in Japan in October 2024 through Meiji Seika Pharma. The company has partnered with CSL Seqirus, a leading global vaccine provider, for development and commercialization of mRNA vaccines targeting COVID-19, influenza, and up to three additional infectious diseases.
The company's competitive advantages rest on its proprietary technology platforms. LUNAR comprises a library of over 300 biodegradable synthetic lipids designed to safely and effectively deliver nucleic acids to disease-relevant target tissues. STARR technology enables self-amplifying mRNA vaccines that generate robust, longer-lasting immune responses at lower dose levels compared to conventional mRNA vaccines. The company possesses significant manufacturing expertise and scalable production processes for complex nucleic acid medicines.
Arcturus maintains a global presence with operations supporting clinical development, manufacturing, and commercialization activities. The company's pipeline includes programs in preclinical and clinical development stages, with ongoing collaborations with academic institutions, government agencies including BARDA and the Department of Defense, and commercial partners advancing its therapeutic and vaccine candidates.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1768224
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arcturus Therapeutics Holdings Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arcturus Therapeutics Holdings Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arcturus Therapeutics Holdings Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arcturus Therapeutics Holdings Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arcturus Therapeutics Holdings Inc.'s last four quarterly filings that the numbers alone won't show?”